Curated News
By: NewsRamp Editorial Staff
March 05, 2026
HeartBeam Enrolls First Patients in Groundbreaking Heart Attack Detection Study
TLDR
- HeartBeam's ALIGN-ACS pilot study could give the company a first-mover advantage in portable heart attack detection technology, potentially capturing a new market segment.
- The HeartBeam System uses cable-free 3D ECG technology to synthesize 12-lead ECGs, with the ALIGN-ACS study generating clinical data to expand its FDA-cleared indications.
- This technology enables earlier heart attack detection outside medical facilities, potentially saving lives by directing patients to appropriate care more quickly.
- HeartBeam's first patients were enrolled in Serbia for a study that could transform cardiac care with portable 3D ECG technology.
Impact - Why it Matters
This development matters because heart attacks remain a leading cause of death worldwide, often with delayed diagnosis that worsens outcomes. Current ECG technology typically requires hospital settings and trained technicians, creating barriers to timely detection. HeartBeam's portable 3D ECG system could revolutionize cardiac care by enabling accurate heart attack detection anywhere—at home, at work, or in ambulances—potentially saving thousands of lives through earlier intervention. For patients with cardiac risk factors, this technology promises greater peace of mind and potentially life-saving early warnings. For healthcare systems, it could reduce emergency room overcrowding and hospital costs while improving cardiac outcomes. The technology's expansion from arrhythmia to heart attack detection represents a significant advancement in telemedicine and remote patient monitoring, aligning with broader trends toward decentralized healthcare delivery.
Summary
HeartBeam (NASDAQ: BEAT), a pioneering medical technology company, has achieved a significant milestone by enrolling the first patients in its ALIGN-ACS pilot study. This study, conducted at the University Clinical Center of Serbia in Belgrade under the leadership of Prof. Dr. Vladan Vukcevic, aims to evaluate the HeartBeam System's potential for heart attack detection. This marks a crucial step toward expanding the system's FDA-cleared indications beyond arrhythmia assessment, potentially transforming how acute cardiac events are identified outside traditional medical facilities.
The HeartBeam System represents a breakthrough as the first cable-free device capable of collecting 3D ECG signals from three non-coplanar directions and synthesizing them into a comprehensive 12-lead ECG. This platform technology, which received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, is designed for portable use wherever patients are located. By delivering actionable heart intelligence to physicians, it could enable the identification of cardiac health trends and acute conditions while directing patients to appropriate care—all without requiring a hospital visit. The company's extensive intellectual property portfolio includes over 20 issued patents supporting this innovative approach to cardiac monitoring.
The news was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio that focuses on biotechnology and life sciences developments. BioMedWire provides comprehensive distribution services including wire solutions through InvestorWire, editorial syndication to thousands of outlets, enhanced press release features, and social media distribution via IBN to millions of followers. This ensures that important medical advancements like HeartBeam's reach investors, healthcare professionals, journalists, and the general public effectively, cutting through information overload to provide timely updates on innovations that could redefine cardiac health management.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Enrolls First Patients in Groundbreaking Heart Attack Detection Study
